

activities of the two genes would be inversely related, with E1a providing a sort of 'flip-flop' control.

The focus on E1a proteins is of particular relevance because they are known to exert a profound effect on cellular metabolism, activating chromosomal genes for both heat shock protein⁵ and β -tubulin proteins⁶. E1a proteins have also been shown to activate certain other cellular genes in recombinant plasmids^{7,8}. In addition, as first reported by Houweling *et al.*⁹, if primary rodent cells are transfected with cloned E1a genes alone, they become immortalized. The mechanism of immortalization is unknown but may be the result of stimulation by E1a proteins of the same cellular proliferative functions that are stimulated by the proteins for the benefit of the adenovirus in infected cells. Perhaps the E1a proteins are mimicking the action of an unidentified endogenous stimulator of cell growth that is under the strict control of extracellular growth regulators.

Since the report of amino acid sequence homology between the E1a and myc oncogene proteins¹⁰ and the finding that either the E1a gene or the myc gene will complement a *ras* oncogene in transforming primary cells^{11,12}, any newly discovered property of myc or E1a is promptly sought in the other. Current evidence correlates myc gene expression with cellular proliferation, a feature perhaps akin to E1a's immortalization function. Myc production is transiently induced when growth factors stimulate resting fibroblasts or T cells to enter the G₁ growth state¹³⁻¹⁵. Regulation of the quantity of myc in the cell may also be important to differentiation. Many cell lineages maintain the ability to proliferate until they acquire markers specific for terminal differentiation, whereupon they withdraw from the cell cycle. During *in vitro* differentiation of the HL60 promyelocytic cell line, the expression of myc declines as the capacity for unlimited cell division is lost and differentiation markers are induced (ref. 16 and refs. therein).

Is there evidence for normal cellular proteins with the properties attributed here to E1a? Once again, a virus gives some useful information. The polyoma virus enhancer, shown by Borrelli *et al.* to be blocked by E1a, is inactive in undifferentiated embryonal carcinoma (EC) cells, but becomes active upon their differentiation (ref. 17 and refs. therein). Perhaps a protein in the undifferentiated cells represses the polyoma enhancer, as does E1a in HeLa cells, and perhaps this protein declines in quantity upon cell differentiation. Further evidence comes from the observation that class I major histocompatibility antigens are absent from undifferentiated EC cells but appear upon differentiation (ref. 18 and refs. therein). Provocatively, the E1a gene of the highly oncogenic strain of adenovirus, adenovirus-12, but not that of adenovirus-2, represses these antigens in transformed rodent cells¹⁹ and Borrelli *et al.* suggest that

their expression relies on an enhancer, which could be the target for adenovirus-12 E1a. Finally, EC cells do seem to have an E1a-like protein, which is indeed lost upon differentiation²⁰.

It is tempting to speculate that cellular proteins possessing activator and repressor functions analogous to those of E1a play a role in gene regulation during the growth and differentiation of cells. By inducing a high level of the proteins, a cell might turn on genes required for cell-cycling and repress other genes that are incompatible with proliferation but required in the resting state or after terminal differentiation. Could myc or a related protein provide such regulation? Experiments assessing any role for myc in gene transcription are scant, but there is a hint that, like E1a, myc can activate heat-shock genes²¹. And, as expected for an E1a-like protein, myc does decrease during EC cell differentiation¹⁴. Little is known about enhancer control, but the existence of tissue-specific enhancers^{22,23} makes it highly probable that there is regulation during differentiation. E1a's intriguing properties are directing us to fundamental features of the control of genes and, with time, all will be revealed. □

1. Khoury, G. & Gruss, P. *Cell* **33**, 313 (1983).
2. Borrelli, E., Hen, R. & Chambon, P. *Nature* **312**, 608 (1984).
3. Berk, A. J., Lee, F., Harrison, T., Williams, J. and Sharp, P. A. *Cell* **17**, 935 (1979).
4. Jones, N. & Shenk, T. *Proc. natn. Acad. Sci. U.S.A.* **76**, 3665 (1979).
5. Kao, H.-T. & Nevins, J. *Mol. Cell Biol.* **3**, 2058 (1983).
6. Stein, R. & Ziff, E. *Mol. Cell Biol.* (in the press).
7. Treisman, R., Green, M. & Maniatis, T. *Proc. natn. Acad. Sci. U.S.A.* **80**, 7428 (1983).
8. Green, M., Treisman, R. & Maniatis, T. *Cell* **35**, 137 (1983).
9. Houweling, A., Van den Elsen, P. J., & Van der Eb, A. J. *Virology* **105**, 537 (1980).
10. Ralston, R. & Bishop, J. M. *Nature* **306**, 803 (1983).
11. Land, H., Parada, L. & Weinberg, R. *Nature* **304**, 596 (1983).
12. Ruley, H. E. *Nature* **304**, 602 (1983).
13. Kelly, K., Cochran, B. H., Stiles, C. D. & Leder, P. *Cell* **35**, 603 (1983).
14. Campisi, J., Gray, H. E., Pardee, A. B., Dean, M. & Sonenshein, G. E. *Cell* **3**, 241 (1984).
15. Greenberg, M. & Ziff, E. *Nature* **311**, 433 (1984).
16. Reitsma, P. H. *et al.* *Nature* **306**, 492 (1983).
17. Katinka, M., Yaniv, M., Vasseur, M. & Blangy, D. *Cell* **20**, 393 (1980).
18. Morello, D. *et al.* *Nature* **296**, 260 (1982).
19. Schrier, P. I., Bernards, R., Vaessen, R., Houweling, A. & Van der Eb, A. *Nature* **305**, 771 (1983).
20. Imperiale, M. J., Kao, H.-T., Feldman, L. T., Nevins, J. R. & Strickland, S. *Mol. Cell Biol.* **4**, 867 (1984).
21. Kingston, R. E., Baldwin, A. S. & Sharp, P. A. *Nature* **312**, 280 (1984).
22. Banerji, I., Olson, L. & Schaffner, W. *Cell* **33**, 729 (1983).
23. Gillies, S., Morrison, S. & Tonegawa, S. *Cell* **33**, 717 (1983).

Anna Velcich and Edward Ziff are in the Department of Biochemistry and the Kaplan Cancer Research, New York University Medical Center, NY 10016, USA.

Low-temperature physics

Do cosmic rays account for superfluid ³He transition?

from P. V. E. McClintock

IN THEORY, the transition between the two principal superfluid forms of liquid ³He ought not to be able to occur. So why is it routinely observed to take place? A possible answer to this intriguing question has recently been put forward by A. J. Leggett. Writing in *Physical Review Letters* **53**, 1096; 1984, he suggests that the transition, although prohibited from occurring spontaneously, readily takes place because of the occasional high energy cosmic ray that passes through any experimental chamber on the Earth's surface.

When helium gas is sufficiently cooled under atmospheric pressure, it eventually — albeit somewhat reluctantly on account of its very weak interatomic forces — condenses to form a colourless liquid. The liquid is of exceptional importance and scientific interest, enjoying the unique distinction of remaining a liquid down to the lowest attainable temperatures. There are two distinct forms of liquid helium, corresponding to the two stable isotopes, ³He and ⁴He. Liquid ⁴He undergoes a superfluid transition at about 2 K, entering a state in which a component of the liquid loses all its viscosity. It thus becomes able to flow quite effortlessly through holes or pores of vanishingly small dimensions; correspondingly, a small object travelling through the superfluid encounters absolutely no resistance to its forward motion. It

requires temperatures about 1,000 times colder for the same sort of behaviour, but in much more complicated form, to be observed in liquid ³He.

When liquid ³He is cooled under a pressure of more than about 20 atmospheres in a weak magnetic field, there is a very rapid onset of superfluidity at about 2 mK. The transition is second order, with no associated latent heat, and it always occurs at the same characteristic temperature for any given pressure. The superfluid phase that results is known as the A-phase. If the liquid is cooled further, it subsequently undergoes a first order transition, to the so-called B-phase superfluid. This transition is analogous to the more familiar phase changes of boiling or freezing, and occurs at a temperature that is not accurately reproducible. To put it another way, if the liquid is being cooled at a steady rate, the time taken for transition from A to B to occur is different on each occasion even if each experiment is carried out with the same cell and, so far as can be determined, in an identical fashion.

There is worse to come. In any pure system close to a phase transition, one can imagine small regions of opposite phase continually forming and disappearing again as the result of thermal fluctuations. Whether any one such region subsequently grows or shrinks will depend both on its

size and on the various bulk and surface energies of the two phases. Thus, ${}^3\text{He-A}$ could be cooled to a temperature where it would 'like' to become ${}^3\text{He-B}$, because the energy of the latter phase is lower, but cannot until a spontaneous thermal fluctuation produces a 'large enough' region of ${}^3\text{He-B}$. Large enough, in this context, means that the increase in the surface energy between the two phases, resulting from a small increase in the radius of the bubble of B-phase, is more than balanced by the corresponding decrease in energy due to the enclosed liquid being in the lower energy state: if this criterion is met, then the bubble of B-phase will obviously tend to expand until it has taken over the whole of the sample, whereupon the transition from A to B will be seen to have occurred.

It is possible to calculate the critical radius for the bubble of ${}^3\text{He-B}$ and hence, by the application of statistical mechanics, to estimate the average length of time before the transition occurs, given any particular degree of supercooling. Even on the most optimistic assumptions about the numerical values of the various parameters, the calculated result is a period of time vastly in excess of the age of the Universe. Hence, the transition should never be observed. And yet, even with a moderate degree of supercooling, the observed transition time is of the order of minutes.

Leggett's solution to this apparent impasse is based upon a consideration of the events that should follow the transit of a cosmic ray muon of about 2 GeV through the supercooled liquid, as can be expected every few minutes. The immediate consequences are reasonably predictable on the basis of detailed studies of high energy particles in helium bubble chambers: a number of relatively low energy electrons would be produced, each of which would give up much of its kinetic energy through the production of heat, initially creating a region of a few hundred Å in radius at a few tenths of a K, while the bulk of the liquid remained at its ambient temperature of 1–2 mK. What would happen next is a matter of some conjecture. Leggett's view is that an expanding shell of heated liquid would be created, propagating out from each original event, with the enclosed liquid cooling towards its ambient temperature. He points out that this 'baked Alaska' distribution would provide ideal conditions for the formation of B-phase ${}^3\text{He}$ as the heated liquid cools through the superfluid transition, and that the cooling would be too rapid for the expansion and domination of any small bubbles of A-phase ${}^3\text{He}$ that might be nucleated at the same time. From the point of view of the experimenter, unaware of the passage of the initiating cosmic ray, the transition from A to B will seem to have taken place spontaneously, a few minutes after the regime of a supercooled A-phase has been entered.

Now that Leggett's suggestion has been

aired, it should not be too difficult to set up suitable particle detectors and a coincidence counting system to test whether the transition coincides with the passage of a cosmic ray through the liquid. If the hypothesis is correct, it will open the way to study the metastable A-phase right down to near-zero temperatures in weak magnetic fields — a matter of considerable experimental and theoretical interest. All

that should be necessary is to shield the sample from cosmic rays, perhaps by conducting the experiments at the bottom of a deep mine. The first experimental test of Leggett's hypothesis will be awaited with very considerable interest. □

P.V.E. McClintock is in the Department of Physics, University of Lancaster, Lancaster LA1 4YB, UK.

Oncogenic intelligence

Cell immortalization and transformation by the *p53* gene

from D.P. Lane

A DIRECT role for the so-called *p53* gene of cells in the process of oncogenesis is suggested by three papers in this issue of *Nature*. Parada *et al.*¹ and Eliyahu *et al.*² both show that the protein encoded by the *p53* gene can complement activated *ras* genes in the transformation of primary rodent cells. The third report, from Jenkins *et al.*³ establishes that the *p53* gene can also immortalize such cells.

The *p53* protein was first detected in the form of its tight non-covalent complex with the large T protein of simian virus 40 (SV40)⁴. Subsequently it was found also to complex to the E1b 58K protein of adenovirus⁵. Though not closely related in structure, both these proteins are involved in the oncogenic action of their viruses, implying that their shared ability to bind the *p53* protein is important for their action in cellular transformation. The *p53* protein in primary cells and established non-transformed cells has a very short half-life and is present in minute concentrations, with each cell containing only a few hundred molecules. When bound to either viral protein, the half-life of *p53* is greatly extended and the protein accumulates, reaching concentrations of the order of 10,000 molecules per cell. Many transformed cell lines and primary tumour isolates also contain elevated levels of the protein^{6,7}. Microinjection of antibodies to *p53* into the cell nucleus of normal quiescent cells prevents their stimulation by serum, implying an important natural role for the protein⁸.

The new discoveries are provocative because they suggest that the alterations in *p53* levels and stability in many mouse and human tumours may be directly involved in their altered growth. Parada *et al.* introduced a cloned *p53* gene (linked to the murine leukaemia virus LTR) into primary rat embryo fibroblasts (REF) and Rat-1 cells. While the *p53* gene alone failed to transform either cell type, when it was introduced together with an activated *ras* gene, foci were produced in the REF cultures. Since the *ras* gene alone was also unable to induce foci, the *p53* gene seems to provide a complementation function in this

assay in much the same way as the cellular *myc* gene, adenovirus E1a gene and the large T gene of polyoma virus^{9,10}. Parada *et al.* further establish that cells transfected with both *p53* and *myc* genes give rise to tumours in nude mice. In both the focus-forming assay and the tumorigenicity test, the *p53* gene appears to be less efficient than the *myc* gene.

Eliyahu *et al.* obtain broadly similar results with either REF cells or Chinese hamster embryo fibroblasts. Again, *p53*, like *myc*, complements an activated *ras* gene in focus-forming assays. Interestingly, this group had some difficulty in establishing cell lines from the foci resulting from introduction of *p53* and *ras* genes together, and obtained evidence to suggest that overproduction of the *p53* protein can be very toxic to the cells.

Jenkins *et al.* go on to prove that *p53* can immortalize cells, thus increasing the strength of the similarity between *p53*, *myc* and E1a. The Wistar adult xiphisternum chondrocyte cells they used have a doubling-time of greater than 60 hours and undergo 30 doublings in culture before senescence and cessation of growth. But after transfection with a plasmid that contained the *p53* gene, early passage cultures of the cells had an extended life (200 doublings so far), a shorter doubling-time in serum, and the ability to be transformed efficiently into tumorigenic cells by an activated *ras* gene.

Since *p53* regulation is altered in so many human tumours, an obvious first priority, now is to look for alterations in the *p53* gene in human neoplasia. But deeper issues can also be addressed. Does SV40 large T have the unusual ability to transform primary cells both readily and directly because it first immortalizes by stabilizing *p53* and then induces morphological transformation by some other *ras*-like activity? If so, why are E1a proteins, rather than the *p53*-stabilizing E1b 58K protein, the immortalizing proteins of adenovirus? Moreover, why do certain small amino-terminal fragments of SV40 large T that are unable to complex *p53*, nevertheless have the ability to immortalize cells¹¹?